Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Colorectal Neoplasms 310Squamous Cell Carcinoma of Head and Neck 163Head and Neck Neoplasms 145Carcinoma, Non-Small-Cell Lung 97Colonic Neoplasms 89Rectal Neoplasms 81Neoplasm Metastasis 70Neoplasms 59Pancreatic Neoplasms 40Carcinoma, Squamous Cell 38Lung Neoplasms 35Esophageal Neoplasms 25Breast Neoplasms 22Stomach Neoplasms 20Recurrence 20Laryngeal Neoplasms 17Carcinoma 17Tongue Neoplasms 16Mouth Neoplasms 16Esophageal Squamous Cell Carcinoma 14Oropharyngeal Neoplasms 13Salivary Gland Neoplasms 12Adenocarcinoma Of Esophagus 12Hypopharyngeal Neoplasms 11Laryngeal Diseases 10Adenocarcinoma of Lung 10Uterine Cervical Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

Docetaxel 6Gemcitabine 3Carboplatin 3lorlatinib 2cemiplimab 2Vinorelbine 2S 1 (combination) 2Pemetrexed 2Erlotinib Hydrochloride 2Cisplatin 2Cetuximab 2zimberelimab 1surufatinib 1sintilimab 1quemliclustat 1pemigatinib 1pembrolizumab 1nimotuzumab 1fludarabine 1WW Domain-Containing Oxidoreductase 1Paclitaxel 1Interleukin-2 1Gene Expression Profiling 1Drug Therapy 1Cyclophosphamide 1Capecitabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Non-Small Cell Lung Cancer × Cetuximab × Clear all
NCT05504278 2025-01-27

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
144 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT00330746 2012-05-18

CALC-1

National Cancer Institute, Naples

Phase 2 Completed
100 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡